ONPATTROTM (Patisiran), the first RNA interference (RNAi) therapeutic drug has been approved by FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults [52]. Here, TTR is linked to polyneuropathy.